AN 788
Alternative Names: AN-788; IP-2018; NSD788Latest Information Update: 26 Sep 2022
Price :
$50 *
At a glance
- Originator NeuroSearch
- Developer Aniona; Initiator Pharma; Saniona
- Class Antidepressants; Anxiolytics
- Mechanism of Action Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Erectile dysfunction
- No development reported Major depressive disorder
- Discontinued Anxiety disorders
Most Recent Events
- 26 Sep 2022 AN 788 is still in phase-II clinical trials for Erectile dysfunction (In adults) in United Kingdom (unspecified route) (EduraCT2020-000469-18) (NCT04686916)
- 26 Jun 2020 Phase-II clinical trials in Erectile dysfunction (In adults) in United Kingdom (unspecified route) (EduraCT2020-000469-18) (NCT04686916)
- 08 Nov 2018 Saniona enters into a option agreement with Initiator Pharma for rights to acquire AN 788